Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
ACS Appl Mater Interfaces. 2022 Sep 21;14(37):41712-41725. doi: 10.1021/acsami.2c10322. Epub 2022 Sep 7.
The intestinal epithelium is known to be a main hindrance to oral delivery of nanoparticles. Even though surface ligand modification can enhance cellular uptake of nanoparticles, the "easy entry and hard across" was frequently observed for many active targeting nanoparticles. Here, we fabricated polymeric nanoparticles relayed by bile acid transporters with monomethoxy poly(ethylene glycol)-poly(D,l-lactide) and deoxycholic acid-conjugated poly(2-ethyl-2-oxazoline)-poly(D,l-lactide) based on structural characteristics of intestine epithelium and the absorption characteristics of endogenous substances. As anticipated, deoxycholic acid-modified polymeric nanoparticles featuring good stability in simulated gastrointestinal fluid could notably promote the internalization of their payload by Caco-2 cells through mediation of apical sodium-dependent bile acid transporter (ASBT) and transmembrane transport of the nanoparticles across Caco-2 cell monolayers via relay-guide of ASBT, ileal bile acid-binding protein, and the heteromeric organic solute transporter (OSTα-OSTβ) along with multidrug resistance-associated protein 3 (MRP3) evidenced by competitive inhibition and fluorescence immunoassay, which was further visually confirmed by the stronger fluorescence from C6-labeled nanoparticles inside enterocytes and the basal side of the intestinal epithelium of mice. The transcellular transport of deoxycholic acid-modified nanoparticles in an intact form was mediated by caveolin/lipid rafts and clathrin with intracellular trafficking trace of endosome-lysosome-ER-Golgi apparatus and bile acid transport route. Furthermore, the increased uptake by HepG2 cells compared with unmodified nanoparticles evidenced the target ability of deoxycholic acid-modified nanoparticles to the liver, which was further supported by ex vivo imaging of excised major organs of mice. Thus, this study provided a feasible and potential strategy to further enhance transepithelial transport efficiency and liver-targeted ability of nanoparticles by means of the specific enterohepatic circulation pathways of bile acid.
肠上皮细胞是阻碍纳米颗粒经口服递送的主要屏障。尽管表面配体修饰可以增强纳米颗粒的细胞摄取,但对于许多主动靶向纳米颗粒,经常观察到“易于进入而难以穿越”的现象。在这里,我们基于肠上皮细胞的结构特征和内源性物质的吸收特征,使用胆酸转运蛋白介导的聚乙二醇-聚(D,L-丙交酯)和去氧胆酸-接枝聚(2-乙基-2-恶唑啉)-聚(D,L-丙交酯)制备了聚合物纳米颗粒。正如预期的那样,在模拟胃肠道液中具有良好稳定性的去氧胆酸修饰的聚合物纳米颗粒可以通过顶端钠依赖性胆酸转运蛋白(ASBT)介导和纳米颗粒通过 ASBT、回肠胆酸结合蛋白和异源有机溶质转运蛋白(OSTα-OSTβ)的接力引导穿过 Caco-2 细胞单层的跨膜转运,显著促进其有效载荷被 Caco-2 细胞内化,同时多药耐药相关蛋白 3(MRP3)被竞争性抑制和荧光免疫测定证实,这通过 C6 标记的纳米颗粒在肠上皮细胞内和肠上皮细胞基底侧的荧光强度进一步得到证实。完整形式的去氧胆酸修饰纳米颗粒的跨细胞转运是通过小窝蛋白/脂筏和网格蛋白介导的,其细胞内轨迹是内体-溶酶体-ER-高尔基体和胆酸转运途径。此外,与未修饰的纳米颗粒相比,HepG2 细胞的摄取增加证明了去氧胆酸修饰的纳米颗粒对肝脏的靶向能力,这进一步得到了从小鼠主要器官离体成像的支持。因此,该研究通过胆酸的特定肠肝循环途径,为进一步提高纳米颗粒的跨上皮转运效率和肝靶向能力提供了一种可行且有潜力的策略。